読み込み中
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
前日終値
$0.994
−$0.036 · -3.50%
日中の時刻はETです。市場データは遅延する場合があります。
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
日中レンジ
現在 $0.994
52週レンジ
現在 $0.994
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
60
適正価値
センチメント
53
まちまち
リスク
61
高リスク
モメンタム
28
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
日中レンジ
現在 $0.994
52週レンジ
現在 $0.994
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1455.6万 USD | 949.9万 USD | 894.5万 USD | 1470.3万 USD | 389.6万 USD |
| 売上原価 | 84.5万 USD | 33.4万 USD | 67.1万 USD | 72.8万 USD | 142.6万 USD |
| 粗利益 | 1371.1万 USD | 916.5万 USD | 827.4万 USD | 1397.5万 USD | 247万 USD |
| 研究開発 | 1772.9万 USD | 1247.2万 USD | 1570.5万 USD | 1398.7万 USD | 3391.4万 USD |
| 販売・一般管理 | 1846万 USD | 1817.1万 USD | 1730.2万 USD | 2250.8万 USD | 1821.2万 USD |
| 営業費用 | 3549万 USD | 3064.3万 USD | 3300.7万 USD | 3649.5万 USD | 5168.1万 USD |
| 受取利息 | 169.1万 USD | 171.5万 USD | 162.9万 USD | 82.9万 USD | 2000 USD |
| 減価償却費と償却費 | 69.9万 USD | 60.9万 USD | 69.2万 USD | 72.7万 USD | 87.3万 USD |
| 営業利益 | −2177.9万 USD | −2147.8万 USD | −2473.3万 USD | −2252万 USD | −4921.1万 USD |
| 純利益 | −6353.3万 USD | −1860.9万 USD | −2148.6万 USD | −2627.3万 USD | −4301.9万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 配当落ち日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
配当 | 2003年12月15日 | $0.08Irregular | — | — |
配当落ち 2003年12月15日
$0.08
Irregular
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI649.81万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM472.23万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF322.93万0.00%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO177.57万0.01%139.17億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB149.42万0.01%108.2億 USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO116.32万0.01%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC59.46万0.05%13.17億 USD0.60%$183+0.11%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC25.06万0.02%10.45億 USD0.20%$86.29+0.43%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
